干燥综合征B细胞:从自身免疫到淋巴瘤发生及新型B细胞靶向治疗的兴起
本文综述干燥综合征(SjD)以B细胞为中心的发病机制,阐述B细胞高活性内型与淋巴瘤风险的关联,并通过一例反复腺体肿胀后发生腮腺黏膜相关淋巴组织淋巴瘤的病例说明该临床困境,最后回顾反映治疗格局从对症治疗转向靶向治疗的新兴B细胞靶向疗法。
要点
- 干燥综合征尚无美国食品药品监督管理局(FDA)批准的改善病情疗法。
- B细胞高活性内型与淋巴瘤风险增加相关。
- 新兴B细胞靶向疗法反映治疗从对症管理转向基于免疫病理的靶向治疗。
核心结论
- 干燥综合征以B细胞为中心,兼具自身免疫和淋巴瘤转化双重作用,新兴B细胞靶向疗法反映治疗格局正从对症管理转向基于疾病免疫病理的靶向治疗。
研究设计与样本
- 本文为综述,检索范围原文未报告。
- 通过一例干燥综合征患者在多年反复腺体肿胀后发生腮腺黏膜相关淋巴组织淋巴瘤的病例展开论述。
主要发现
- 干燥综合征患者常出现影响不同器官系统的腺外表现。
- B细胞通过产生自身抗体、呈递抗原和释放促炎细胞因子在干燥综合征发病中起核心作用。
- B细胞高活性驱动的干燥综合征内型与淋巴瘤风险增加相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)-approved disease-modifying therapies for SjD. In this review, we explore the expanding field of SjD endotyping as a tool to enhance patient stratification, prognostication, and clinical decision-making. SjD endotypes driven by heightened B cell activity are linked to increased lymphoma risk. B cells play a central role in SjD pathogenesis by producing autoantibodies, presenting antigens, and releasing proinflammatory cytokines. These functions contribute not only to autoimmunity but also to lymphomatous transformation. We illustrate these concepts through the case of a patient with SjD who developed parotid mucosa-associated lymphoid tissue lymphoma after years of recurrent glandular swelling-highlighting a common yet challenging scenario for practicing rheumatologists. Using this case as a framework, we examine the pathobiology of B cells in SjD that drive autoreactivity and lymphomagenesis. Finally, we review emerging B cell-targeted therapies that reflect a broader shift in the SjD treatment landscape from symptomatic management to targeted therapies grounded in disease immunopathology.
引用
- Gordon RA, McCoy SS. Sjögren Disease-B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell-Targeted Therapies. Arthritis Rheumatol. 2026. PMID: 41017162. doi:10.1002/art.43404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。